ROCKVILLE, Maryland, April 29, 2024 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) today announced that it has entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd (“Camtech”), a Singapore family office for US$218,000. The transaction follows Camtech’s prior acquisition of all assets, rights and businesses of Curetis GmhH (“Curetis”), the Company’s subsidiary, from Unyvero, as part of Curetis’ insolvency proceedings.
Additionally, the Company’s subsidiary, Ares Genetics GmbH, sold all of its assets, including the ARESdb database and intellectual property portfolio to bioMerieux SA, as part of Ares Genetics’ insolvency process. Since the sales of Curetis and Ares Genetics assets occurred as part of their insolvency proceedings, OpGen did not participate or have any involvement in such transactions.
OpGen plans to work with Camtech and the Curetis team over the next few months to transfer and transition its U.S. customers and Unyvero business. OpGen also offered Camtech the opportunity to acquire its remaining inventory of Unyvero systems for up to an additional $176,000. Until the sale of remaining inventory is completed, OpGen will maintain business operations and service support for Unyvero systems.
OpGen President and CEO David Lazar commented: “These transactions are consistent with our strategy of preparing OpGen for a potential strategic transaction, including a potential reverse merger of a private company into OpGen. We believe a strategic transaction would be an attractive proposition for OpGen shareholders who could benefit from future value growth.”
About OpGen
(Rockville, Maryland, USA) is a precision medicine company that harnesses the power of molecular diagnostics and bioinformatics to help combat infectious diseases. The company distributes molecular microbiology solutions that help guide clinicians with faster, actionable information about life-threatening infections to improve patient outcomes and slow the spread of infections caused by multidrug-resistant microorganisms, or MDROs.
For more information please visit www.opgen.com
Forward-Looking Statements
This press release includes statements regarding the sale of certain assets, as well as the sale of assets by the Company’s subsidiaries as part of their insolvency proceedings. These statements and other statements regarding OpGen’s future plans and objectives constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and could cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to regain compliance with the Nasdaq Listing Rules, our ability to continue to finance our business and operations, and our liquidity and capital needs of rotation. For a discussion of the most significant risks and uncertainties associated with OpGen’s business, please see our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
OpGen:
David E. Lazar
CEO
InvestorRelations@opgen.com
